General
Preferred name
SEVELAMER
Synonyms
Sevelamer HCl ()
SEVELAMER CARBONATE ()
Renvela ()
Sevelamer anhydrous ()
Renagel ()
GT335-012 ()
GT-335-012 ()
P&D ID
PD009866
CAS
182683-00-7
198342-66-4
52757-95-6
845273-93-0
Tags
available
drug
Drug Status
approved
Max Phase
Phase 4
First approval
2007
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION
Not absorbed following oral administration, however no absorption studies have been performed in patients with renal disease. Sevelamer may bind to dietary phosphates and prevent its gastrointestinal absorption when sevelamer is administered in combination with food.
DESCRIPTION
Sevelamer is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease. It consists of polyallylamine that is crosslinked with epichlorohydrin.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
6
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
Other bioactive compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
42
Molecular Weight
149.06
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
1
Aromatic Ring Count
0
cLogP
0.76
TPSA
38.55
Fraction CSP3
0.67
Chiral centers
1.0
Largest ring
3.0
QED
0.36
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
FXR
Pathway
Metabolic Enzyme/Protease
Source data
